{"id":50087,"date":"2022-10-26T13:02:56","date_gmt":"2022-10-26T11:02:56","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\/"},"modified":"2022-10-26T13:02:56","modified_gmt":"2022-10-26T11:02:56","slug":"expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\/","title":{"rendered":"Expansion Therapeutics Appoints Raymond Kelleher, M.D., Ph.D., to its Board of Directors"},"content":{"rendered":"
\n

\n–Accomplished neurologist and recognized industry leader brings deep scientific and clinical experience to Expansion board<\/i>\n<\/p>\n

BOSTON–(BUSINESS WIRE)–Expansion Therapeutics, Inc., a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases, today announced the appointment of Raymond J. Kelleher, M.D., Ph.D., to its Board of Directors representing Cormorant Asset Management. Dr. Kelleher is an accomplished neurologist and neuroscientist, company founder, and investor, who serves on several boards for leading biotechnology and pharmaceutical companies.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cWe are delighted to welcome Dr. Kelleher to our board as we advance the development of our pipeline of small molecule medicines for severe RNA-mediated neurodegenerative diseases,\u201d said Renato Skerlj, Ph.D., Chief Executive Officer and President of Expansion Therapeutics. \u201cHis depth and breadth of neurology experience coupled with his broad scientific, clinical and industry knowledge will be invaluable as we continue to build Expansion as a leading company in developing transformative oral medicines that could dramatically change patient outcomes for diseases where treatment options are currently limited.\u201d\n<\/p>\n

\nScott Rocklage, Ph.D., Board Chairman added, \u201cWe look forward to collaborating with Dr. Kelleher and benefiting from his extensive board and leadership experience at both large and small innovative pharmaceutical and biotech companies. His contributions to Expansion will provide tremendous support for the company\u2019s continued growth and development.\u201d\n<\/p>\n

\nDr. Kelleher currently serves as Managing Director at Cormorant Asset Management in charge of investing in private and public companies across a range of therapeutic areas. He represents Cormorant on the boards of Arkuda Therapeutics, BiVACOR, and ONK Therapeutics as director, and Chroma Therapeutics, Umoja Biopharma, Interius BioTherapeutics, Garuda Therapeutics, and DTx Pharma as board observer.\n<\/p>\n

\nHe also serves on the faculty at Massachusetts General Hospital and Harvard Medical School, where his laboratory has made important contributions to understanding the molecular and cellular basis of cognition and cognitive disorders. His work has been widely published in Cell, Nature, Neuron, PNAS, and elsewhere, and his research accomplishments have been recognized with national awards including the Pew Scholars Award in the Biomedical Sciences, the John Merck Scholars Award, and the National Institutes of Health Independent Scientist Award. Dr. Kelleher also maintains an active clinical neurology practice at Massachusetts General Hospital specializing in neurodegenerative disorders, particularly Alzheimer\u2019s disease and related dementias.\n<\/p>\n

\n\u201cI look forward to partnering with Expansion\u2019s leadership team and board as the company progresses its pipeline of novel RNA-targeted drug candidates through preclinical and clinical development,\u201d said Dr. Kelleher. \u201cExpansion\u2019s differentiated platform holds tremendous promise in delivering disease-modifying therapies to treat a wide range of RNA-mediated diseases that have the potential to transform patients\u2019 lives.\u201d\n<\/p>\n

\nDr. Kelleher received B.S. degrees in biology and literature from Massachusetts Institute of Technology, an M.A. in french from Harvard, and an M.D. and Ph.D. in cell biology from Stanford, where he discovered the mediator of transcriptional activation while working with Nobel Laureate Roger Kornberg. He conducted postdoctoral research at Massachusetts Institute of Technology with Nobel Laureate Susumu Tonegawa, where he discovered a key role for translational control in memory formation. He completed his internship in internal medicine and residency in neurology at the Massachusetts General Hospital and Harvard Medical School.\n<\/p>\n

\nAbout Expansion Therapeutics
\n
<\/b>Expansion Therapeutics is a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases including neurodegenerative disorders. Based on exclusive worldwide rights to groundbreaking research from the laboratory of Matthew D. Disney, Ph.D., at Scripps Research, Expansion has assembled the intellectual property, know-how, and proprietary enabling technologies and tools necessary to facilitate the creation of potent and specific small molecule RNA modulators. Through this unique platform, Expansion is building a portfolio of novel RNA-targeted drug candidates with activity across a broad number of severe RNA-mediated disease indications. Expansion has sites in Boston and Cambridge, Massachusetts and Jupiter, Florida. For more information, visit www.expansionrx.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/b>
Mike Beyer
\n
Sam Brown Inc.
\n
312-961-2502
\n
mikebeyer@sambrown.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

–Accomplished neurologist and recognized industry leader brings deep scientific and clinical experience to Expansion board BOSTON–(BUSINESS WIRE)–Expansion Therapeutics, Inc., a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases, today announced the appointment of Raymond J. Kelleher, M.D., Ph.D., to its Board of Directors representing Cormorant Asset Management. Dr. Kelleher is an … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50087","6":"format-standard","7":"category-industry"},"yoast_head":"\nExpansion Therapeutics Appoints Raymond Kelleher, M.D., Ph.D., to its Board of Directors - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Expansion Therapeutics Appoints Raymond Kelleher, M.D., Ph.D., to its Board of Directors - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"–Accomplished neurologist and recognized industry leader brings deep scientific and clinical experience to Expansion board BOSTON–(BUSINESS WIRE)–Expansion Therapeutics, Inc., a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases, today announced the appointment of Raymond J. Kelleher, M.D., Ph.D., to its Board of Directors representing Cormorant Asset Management. Dr. Kelleher is an ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-26T11:02:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221026005129\/en\/1613588\/21\/Raymond_Kelleher_Photo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Expansion Therapeutics Appoints Raymond Kelleher, M.D., Ph.D., to its Board of Directors\",\"datePublished\":\"2022-10-26T11:02:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\\\/\"},\"wordCount\":665,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221026005129\\\/en\\\/1613588\\\/21\\\/Raymond_Kelleher_Photo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\\\/\",\"name\":\"Expansion Therapeutics Appoints Raymond Kelleher, M.D., Ph.D., to its Board of Directors - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221026005129\\\/en\\\/1613588\\\/21\\\/Raymond_Kelleher_Photo.jpg\",\"datePublished\":\"2022-10-26T11:02:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221026005129\\\/en\\\/1613588\\\/21\\\/Raymond_Kelleher_Photo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221026005129\\\/en\\\/1613588\\\/21\\\/Raymond_Kelleher_Photo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Expansion Therapeutics Appoints Raymond Kelleher, M.D., Ph.D., to its Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Expansion Therapeutics Appoints Raymond Kelleher, M.D., Ph.D., to its Board of Directors - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Expansion Therapeutics Appoints Raymond Kelleher, M.D., Ph.D., to its Board of Directors - Pharma Trend","og_description":"–Accomplished neurologist and recognized industry leader brings deep scientific and clinical experience to Expansion board BOSTON–(BUSINESS WIRE)–Expansion Therapeutics, Inc., a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases, today announced the appointment of Raymond J. Kelleher, M.D., Ph.D., to its Board of Directors representing Cormorant Asset Management. Dr. Kelleher is an ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-26T11:02:56+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221026005129\/en\/1613588\/21\/Raymond_Kelleher_Photo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Expansion Therapeutics Appoints Raymond Kelleher, M.D., Ph.D., to its Board of Directors","datePublished":"2022-10-26T11:02:56+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\/"},"wordCount":665,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221026005129\/en\/1613588\/21\/Raymond_Kelleher_Photo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\/","url":"https:\/\/pharma-trend.com\/en\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\/","name":"Expansion Therapeutics Appoints Raymond Kelleher, M.D., Ph.D., to its Board of Directors - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221026005129\/en\/1613588\/21\/Raymond_Kelleher_Photo.jpg","datePublished":"2022-10-26T11:02:56+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221026005129\/en\/1613588\/21\/Raymond_Kelleher_Photo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221026005129\/en\/1613588\/21\/Raymond_Kelleher_Photo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/expansion-therapeutics-appoints-raymond-kelleher-m-d-ph-d-to-its-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Expansion Therapeutics Appoints Raymond Kelleher, M.D., Ph.D., to its Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50087"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50087\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}